New Cuban drug with “very encouraging” results against COVID-19

by OnCuba Staff

The Cuban drug known so far as CIGB-300 is showing “very encouraging” results against COVID-19 in its first phase of clinical evaluation, according to the official media.

The antiviral-action drug was designed by the Center for Genetic Engineering and Biotechnology (CIGB) in Havana, and is being studied as part of the research being carried out by Cuban science to confront the pandemic, the BioCubaFarma business group said on Facebook.

“With previously demonstrated antitumor efficacy,” the CIGB-300 is the subject of a controlled clinical trial that started last May in patients positive for SARS-CoV-2, pointed out Cubadebate, which doesn’t offer conclusive or preliminary statistics about the trial.

The study seeks to find out the efficacy of this drug against the SARS-CoV-2 coronavirus, following the steps of research carried out with other drugs, which have also had good results.

In total, the CIGB is currently working on 16 lines of research related to the treatment and control of COVID-19, according to Dr. Gerardo Guillén, director of biomedical research at the renowned scientific institution.

The post about “New Cuban drug with “very encouraging” results against COVID-19" first appeared on the OnCuba News website.


To engage in helping and supporting our Latin American community impacted by the COVID-19 crisis, seek or share information, events, news, forums, and critical connection and collaboration opportunities during this time of mass isolation, join our community at COVID-19 Support Group.

Not yet a member? Get connected and be inspired by more incredible Latin American and Australian professionals. Join the growing Somos21 Community.

Other news